Enterprise Value
-49.39M
Cash
548.9M
Avg Qtr Burn
-46.04M
Short % of Float
9.11%
Insider Ownership
9.93%
Institutional Own.
79.59%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Latozinemab (AL001) (progranulin) Details Frontotemporal dementia with a granulin mutation, Dementia | Phase 3 Data readout | |
AL101 (GSK4527226) (Progranulin) Details Alzheimer's disease, Parkinson's disease, Neurological disorder | Phase 2 Data readout | |
AL002 (TREM 2) Details Alzheimer's disease | Phase 2 Data readout | |
Latozinemab (AL001) (progranulin) Details Dementia, Frontotemporal dementia with C9orf72 mutation, Amyotrophic lateral sclerosis | Phase 2 Update | |
AL003 (SIGLEC 3) Details Alzheimer's disease | Failed Discontinued |